摘要
目的探讨《2023年国家基本医疗保险、工伤保险和生育保险药品目录调整通过初步形式审查的申报药品名单》(简称《申报药品名单》)中待谈判中成药的经济性。方法系统检索PubMed、中国知网、万方、中国生物医学文献服务系统,获取各数据库自建库起至2023年8月公开发表的《申报药品名单》中待谈判中成药的药物经济学文献,汇总文献的基本情况、研究概况、药物经济学评价方法与内容,并使用卫生经济学评价报告标准共识(CHEERS)清单评价文献质量。结果共纳入31篇文献,均为中文文献,涉及《申报药品名单》中7个待谈判中成药(参一胶囊、丹红注射液、复方丹参滴丸、银杏二萜内酯葡胺注射液、银杏内酯注射液、注射用丹参多酚酸和注射用益气复脉),其中14项研究表明待评价药品具有良好的经济性。CHEERS清单评价,纳入文献的平均得分为13.3分,中位得分为11.5分。结论现有研究表明,《申报药品名单》中待谈判中成药缺乏高质量的药物经济学研究支持,亟需高质量的中成药药物经济学研究来支撑其纳入《国家基本医疗保险、工伤保险和生育保险药品目录》(简称《国家医保目录》)。
Objective To investigate the economy of Chinese patent medicines to be negotiated in the Drug List Through the Preliminary Form of Examination in the National Reimbursement Drug List in 2023(hereinafter referred to as the Drug List).Methods The pharmacoeconomics studies related to Chinese patent medicines to be negotiated in the Drug List in the PubMed,CNKI,WanFang and SinoMed from the inception of each database to August 2023 were systematically searched,the basic information,research summary,pharmacoeconomics evaluation methods and content of studies were summarized,and the quality of studies was evaluated by the Consolidated Health Economic Evaluation Reporting Standards(CHEERS)checklist.Results A total of 31 studies were included,all in Chinese,involving seven Chinese patent medicines to be negotiated in the Drug List(Shenyi Capsules,Danhong Injection,Compound Danshen Dropping Pills,Diterpene Ginkgolide Meglumine Injection,Ginkgolide Injection,Salvianolate Lyophilized Injection and Yiqi Fumai Injection),of which 14 studies showed that the drugs to be evaluated were economical.The CHEERS checklist evaluation showed an average score of 13.3 points for the included studies,with a median score of 11.5 points.Conclusion The existing studies show that high-quality pharmacoeconomics studies to support Chinese patent medicines to be negotiated in the Drug List included in the National Reimbursement Drug List were lacked,so it is urgent to improve the quality of studies.
作者
郑雅婷
谭重庆
王勇
ZHENG Yating;TAN Chongqing;WANG Yong(Guangdong Women and Children Hospital,Guangzhou,Guangdong,China 511442;The Second Xiangya Hospital of Central South University,Changsha,Hunan,China 410011;Guangdong Pharmaceutical Association,Guangzhou,Guangdong,China 510080)
出处
《中国药业》
CAS
2023年第24期19-24,共6页
China Pharmaceuticals
基金
国家自然科学基金[82073818]。
关键词
中成药
药物经济学
待谈判药品
《国家医保目录》
系统评价
Chinese patent medicine
pharmacoeconomics
drug to be negotiated
National Reimbursement Drug List
systematic review
